• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Merck KGaA, Quris-AI Extend Current Collaboration


Deal comes amid first successful partnership.

scientist handling a micro pipette, with the lab high-tech equipment. Modern and pristine laboratory. Image Credit: Adobe Stock Images/olga_demina

Image Credit: Adobe Stock Images/olga_demina

Quris-AI announced in a company press release that it has agreed to expand its existing partnership with Merck KGaA. Following the success of its first collaboration, a preclinical study to assess Quris-AI’s ability to predict drug toxicity in comparison to traditional in vitro and in vivo approaches, Merck KGaA has the option to obtain up to a five-year exclusive license to a specific disease domain. Upon exercising the option, Quris-AI may receive an undisclosed amount.

“Based on the results of our initial collaboration, we are looking forward to exploring how its BioAI platform can advance our drug development and testing programs, and working towards an AI-enabled IND process that reduces the reliance on animal testing,” said Danny Bar-Zohar, global head, research & development, chief medical officer, healthcare business sector, Merck KGaA, Darmstadt, Germany, in a company press release. “If we could better focus on developing safe and effective drug candidates, we would be able to reduce significant time and cost investments.”

Reference: Merck KGaA, Darmstadt, Germany and Quris-AI Expand Collaboration. Quris-AI. September 28, 2023. Accessed September 28, 2023. https://www.quris.ai/merckkgaa-quris-ai-expand-collaboration

Related Videos
Related Content